A 1-year randomized Phase III core trial (NCT00061750) using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for an additional 4 years. The objective of this study is to assess the efficacy and long-term safety of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
506
Tablets taken orally once a day.
Children's Hospital Los Angeles
Los Angeles, California, United States
Children's Hospital and Research Center at Oakland
Oakland, California, United States
Stanford Hospital, Division of Oncology
Stanford, California, United States
Children's Memorial Hospital
Chicago, Illinois, United States
Children's Hospital Boston, Dept of Hematology
Boston, Massachusetts, United States
Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event
Adverse events results are based on preferred terms with at least 7% of participants in any group.
Time frame: up to 5 years
Long-term Effect of ICL670 on Hepatic Iron Stores Measured by Means of Liver Iron Content (LIC) as Assessed by Liver Biopsy
Mean absolute change of LIC from start of Deferasirox (ICL670) treatment to the end of study assessed by liver biopsy. Reported in milligrams of Iron per gram dry weight (mg Fe/g dw).
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Long-term Effect of ICL670 on Hepatic Iron Stores Measured by Means of Liver Iron Content (LIC) as Assessed by SQUID
Mean absolute change in LIC from start of Deferasirox (ICL670) treatment to the end of the study assessed by Superconducting Quantum Interfering Device (SQUID) measurement used as a non-invasive alternative to Biopsy for pediatric participants. Reported in milligrams of Iron per gram dry weight (mg Fe/g dw).
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Long-term Effect of Treatment With ICL670 on the Changes in Serum Ferritin Levels From Start of ICL670 Treatment to End of Study
Mean Absolute Change in serum ferritin (ug/L) from start of treatment with Deferasirox (ICL670) to end of study taking into account the therapeutic goal which will either be to maintain iron balance or to induce negative iron balance. End of study taken as the mean of, at most, the last three available results after start of treatment with ICL670.
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Change in Surrogate Marker: Serum Transferrin From Start of Treatment With ICL670 to End of Study
Measurement of the relative change in percent of potential surrogate marker: Serum Transferrin (g/L) from start of treatment with Deferasirox (ICL670) to end of study. (Serum Transferrin at the End of Study-Serum Transferrin at Start of ICL670)/Serum Transferrin at Start of ICL670\*100.
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Change in Surrogate Marker: Serum Iron From Start of Treatment With ICL670 to End of Study
Measurement of the relative change of potential surrogate markers: Serum Iron (µmol/L) from start of treatment with Deferasirox (ICL670) to end of study. (Serum Iron at the End of Study-Serum Iron at Start of ICL670)/Serum Iron at Start of ICL670\*100.
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Change in Surrogate Marker: Transferrin Saturation From Start of Treatment With ICL670 to End of Study
Measurement of the relative change of potential surrogate marker: Transferrin Saturation (Percent) from start of treatment with Deferasirox (ICL670) to end of study. (Transferrin Saturation at the End of Study-Tranferrin Saturation at Start of ICL670)/Transferrin Saturation at Start of ICL670\*100.
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Absolute Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by Biopsy
Measurement of median absolute change in liver iron content (LIC) from start of treatment with Deferasirox (ICL670) to end of study obtained through biopsy. Absolute change = End of study value - start of treatment value. LIC is expressed in mg of iron per gram of liver dry weight (mg Fe/g dw).
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Relative Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by Biopsy
Relative change in liver iron content (LIC) as measured by biopsy and calculated by: End of study value - Start of ICL670 treatment value (absolute change) / Start of ICL670 treatment value.
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Absolute Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by SQUID
Measurement of the median absolute change in liver iron content (LIC) from start of treatment with Deferasirox (ICL670) to end of study obtained through Superconducting Quantum Interfering Device (SQUID). Absolute change = End of study value - start of treatment value. LIC is expressed in mg of iron per gram of liver dry weight (mg Fe/g dw).
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Relative Change in Liver Iron Content From Start of ICL670 Treatment to End of Study as Measured by SQUID
Relative change in liver iron content (LIC) measured by Superconducting Quantum Interfering Device (SQUID), calculated by: End of study value - Start of ICL670 treatment value (absolute change) / Start of ICL670 treatment value.
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
Change of Total Body Iron Excretion Rate (TBIE) From Start of ICL670 Treatment to the End of Study
Median change in TBIE (mg/kg/day) from start of treatment with Deferasirox (ICL670) to end of study.
Time frame: Start of ICL670 treatment, End of Study or study discontinuation (up to 5 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Laken, Belgium
...and 39 more locations